OUTI KUITTINEN

Contact info

Research groups

• Kuopio and Oulu translational and clinical lymphoma study group
• Effectiveness of cancer diagnostic and therapy, attitudes of patients and physicians, and how patients socioeconomical status interferes these aspects

Publications

• Chan, Mikko C.; Savela, Janette; Ollikainen, Riina K.; Teppo, Hanna-Riikka; Miinalainen, Ilkka; Pirinen, Risto; Kuitunen, Hanne; Kari, Esa J. M.; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi; Kuusisto, Milla E. L.. 2021. Testis-Specific Thioredoxins TXNDC2, TXNDC3, and TXNDC6 Are Expressed in Both Testicular and Systemic DLBCL and Correlate with Clinical Disease Presentation Oxidative medicine and cellular longevity 2021: 8026941. 2021
• Rajamäki, Aino; Sunela, Kaisa; Prusila, Roosa E. I.; Kuusisto, Milla E. L.; Mercadal, Santiago; Selander, Tuomas; Kuitunen, Hanne; Pollari, Marjukka; Jantunen, Esa; Nystrand, Ilja; Sancho, Juan-Manuel; Sorigue, Marc; Kuittinen, Outi. 2021. Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months Leukemia & lymphoma [Epub ahead of print 5 Feb 2021]: 1-9. 2021
• Tokola, Susanna; Kuitunen, Hanne; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi. 2020. Significance of bulky mass and residual tumor - Treated with or without consolidative radiotherapy - To the risk of relapse in DLBCL patients Cancer medicine 9 6: 1966-1977. 2020
• Turunen, Antti; Valtola, Jaakko; Partanen, Anu; Ropponen, Antti; Kuittinen, Outi; Kuitunen, Hanne; Vasala, Kaija; Ågren, Lasse; Penttilä, Karri; Keskinen, Leena; Savolainen, Eeva-Riitta; Pyörälä, Marja; Kuittinen, Taru; Selander, Tuomas; Mäntymaa, Pentti; Pelkonen, Jukka; Jantunen, Esa; Varmavuo, Ville. 2020. Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study Leukemia & lymphoma 61 9: 2082-2092. 2020
• Turunen, Antti; Partanen, Anu; Valtola, Jaakko; Ropponen, Antti; Siitonen, Timo; Kuittinen, Outi; Kuitunen, Hanne; Putkonen, Mervi; Sankelo, Marja; Keskinen, Leena; Savolainen, Eeva-Riitta; Pyörälä, Marja; Kuittinen, Taru; Silvennoinen, Raija; Penttilä, Karri; Sikiö, Anu; Vasala, Kaija; Mäntymaa, Pentti; Pelkonen, Jukka; Varmavuo, Ville; et al.. 2020. CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter Goa study Transfusion 60 7: 1519-1528. 2020
• Uotila, PM; Lemma, SA; Haapasaari, KM; Porvari, K; Skarp, S; Soini, Y; Jantunen, E; Turpeenniemi-Hujanen, T; Kuittinen, O. 2020. Prognostic significance of Twist, ZEB1 and Slug in peripheral T-cell lymphomas Hematology 25 1: 241-246. 2020
• Partanen, Anu; Turunen, Antti; Valtola, Jaakko; Pyörälä, Marja; Vasala, Kaija; Kuittinen, Outi; Kuitunen, Hanne; Penttilä, Karri; Keskinen, Leena; Kuittinen, Taru; Mäntymaa, Pentti; Pelkonen, Jukka; Varmavuo, Ville; Jantunen, Esa. 2020. Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study Transfusion 2021; 61 2: 516-525. 2020
• Partanen, A; Turunen, A; Valtola, J; Pyörälä, M; Vasala, K; Kuittinen, O; Kuitunen, H; Penttilä, K; Kuittinen, T; Mäntymaa, P; Pelkonen, J; Varmavuo, V Jantunen, E. 2020. Autologous stem cell transplantation in peripheral T-cell lymphoma: better mobilization of blood CD34 + cells is associated with improved survival Leukemia & lymphoma 61 12: 3027-3029. 2020
• Kuitunen, H; Kaprio, E; Karihtala, P; Makkonen, V; Kauppila, S; Haapasaari, KM; Kuusisto, M; Jantunen, E; Turpeenniemi-Hujanen, T; Kuittinen, O. 2020. Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma Annals of hematology 99 8: 1823-1831. 2020
• Kari, Esa Jarkko Mikael; Kuusisto, Milla Elvi Linnea; Honkavaara, Päivi; Hakalahti, Anna; Haapasaari, Kirsi-Maria; Bloigu, Risto; Karihtala, Peeter; Teppo, Hanna-Riikka; Pirinen, Risto; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi. 2020. Thioredoxin-1 as a Biological Predictive Marker for Selecting Diffuse Large B-cell Lymphoma Patients for Etoposide-Containing Treatment European journal of haematology 105 2: 156-163. 2020
• Eskelund, Christian Winther; Dimopoulos, Kostas; Kolstad, Arne; Glimelius, Ingrid; Räty, Riikka; Gjerdrum, Lise Mette Rahbek; Sonnevi, Kristina; Josefsson, Pär; Nilsson-Ehle, Herman; Bentzen, Hans HN; Fagerli, Unn Merete; Kuittinen, Outi; Haaber, Jacob; Niemann, Carsten Utoft; Pedersen, Lone Bredo; Larsen, Maria Torp; Geisler, Christian Hartmann; Hutchings, Martin; Jerkeman, Mats; Grønbæk, Kirsten. 2020. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3 HemaSphere 2021; 5 1: e510. 2020
• Häyrinen, MJ; Uotila, PM; Sahi, H; Haapasaari, KM; Teppo, HR; Soini, Y; Lapela, M; Vasala, K; Turpeenniemi-Hujanen, T; Ranki, A; Kuusisto, MEL; Kuittinen, O. 2019. Twist and Zeb1 expression identify Mycosis fungoides patients with low risk of disease progression Journal of the european academy of dermatology and venereology 2020; 34 2: e95-e98. 2019
• Kari, E; Teppo, HR; Haapasaari, KM; Kuusisto, MEL; Lemma, A; Karihtala, P; Pirinen, R; Soini, Y; Jantunen, E; Turpeenniemi-Hujanen, T; Kuittinen, O. 2019. Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP Journal of clinical pathology 72 4: 316-321. 2019
• Kari, EJM; Kuusisto, MEL; Böhm, J; Haapasaari, KM; Teppo, HR; Karihtala, P; Hakalahti, A; Turpeenniemi-Hujanen, T; Kuittinen, O. 2019. Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma Anticancer research 39 9: 4925-4931. 2019
• Prusila, REI; Sorigue, M; Jauhiainen, J; Mercadal, S; Postila, A; Salmi, P; Tanhua, T; Tikkanen, S; Kakko, S; Kuitunen, H; Pollari, M; Nystrand, I; Kuusisto, MEL; Vasala, K; Jantunen, E; Korkeila, E; Karihtala, P; Sancho, JM; Turpeenniemi-Hujanen, T; Kuittinen, O. 2019. Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era British journal of haematology 187 3: 364-371. 2019
• Sorigue, M; Bishton, M; Domingo-Domenech, E; McMillan, A; Prusila, R; García, O; Kuusisto, M; Condom, M; Tapia, G; Ribera, JM; Kuittinen, O; Fox, CP; Sancho, JM. 2019. Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma Leukemia & lymphoma 60 10: 2524-2531. 2019
• Sorigue, M; Prusila, REI; Jauhiainen, J; Mercadal, S; Postila, A; Salmi, P; Tanhua, T; Tikkanen, S; Kakko, S; Kuitunen, H; Pollari, M; Nystrand, I; Kuusisto, MEL; Vasala, K; Jantunen, E; Korkeila, E; Karihtala, P; Sancho, JM; Turpeenniemi-Hujanen, T; Kuittinen, O. 2019. Incidence of solid cancer in patients with follicular lymphoma Acta oncologica 58 11: 1564-1569. 2019
• Knuutinen, O; Kuitunen, H; Alahuhta, S; Isokangas, J-M; Sonkajärvi, E; Turpeenniemi-Hujanen, T; Kuittinen, O. 2018. Case report: Chemotherapy in conjunction with blood-brain barrier disruption for a patient with germ cell tumor with multiple brain metastases Clinical genitourinary cancer 16 5: e993-e996. 2018
• Peroja, P; Pedersen, M; Mantere, T; Nørgaard, P; Peltonen, J; Haapasaari, KM; Böhm, J; Jantunen, E; Turpeenniemi-Hujanen, T; Rapakko, K; Karihtala, P; Soini, Y; Vasala, K; Kuittinen, O. 2018. Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP Scientific Reports 8 1: 14814. 2018
• Prusila, Roosa Enni Inkeri; Haapasaari, Kirsi-Maria; Marin, Katja; Pollari, Marjukka; Soini, Ylermi; Vornanen, Martine; Karjalainen-Lindsberg, Marja-Liisa; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi. 2018. R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma Acta oncologica 57 9: 1265-1267. 2018
• Prusila, Roosa; Peroja, Pekka; Jantunen, Esa; Turpeenniemi-Hujanen, Taina; Kuittinen Outi. 2018. Treatment of Diffuse Large B-cell Lymphoma in Elderly Patients: Replacing Doxorubicin with either Epirubicin or Etoposide (VP-16) Hematological oncology 2019; 37 2: 136-142. 2018